Opthea Limited Unsponsored ADR (NASDAQ:OPT) Given Average Rating of “Hold” by Brokerages

Opthea Limited Unsponsored ADR (NASDAQ:OPT) has earned a consensus rating of “Hold” from the seven analysts that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $1.3333.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Opthea in a research report on Monday.

Institutional Investors Weigh In On Opthea

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. EP Wealth Advisors LLC acquired a new position in Opthea during the first quarter valued at approximately $34,000. OLD Mission Capital LLC increased its holdings in shares of Opthea by 78.7% in the first quarter. OLD Mission Capital LLC now owns 19,167 shares of the company’s stock worth $65,000 after acquiring an additional 8,439 shares in the last quarter. Regal Partners Ltd lifted its holdings in shares of Opthea by 78.6% during the 1st quarter. Regal Partners Ltd now owns 5,193,688 shares of the company’s stock valued at $17,710,000 after purchasing an additional 2,286,285 shares in the last quarter. Finally, Twin Lakes Capital Management LLC grew its position in shares of Opthea by 67.4% in the 1st quarter. Twin Lakes Capital Management LLC now owns 33,156 shares of the company’s stock valued at $113,000 after purchasing an additional 13,350 shares during the period. Institutional investors own 55.95% of the company’s stock.

Opthea Stock Performance

Opthea has a 12 month low of $1.79 and a 12 month high of $6.30. The stock’s fifty day simple moving average is $3.41 and its 200-day simple moving average is $3.41.

Opthea Company Profile

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.